Short Interest in Ainos, Inc. (NASDAQ:AIMD) Drops By 46.6%

Ainos, Inc. (NASDAQ:AIMD) was the recipient of a significant decline in short interest during the month of October. As of October 15th, there was short interest totaling 12,400 shares, a decline of 46.6% from the September 30th total of 23,200 shares. Currently, 0.6% of the shares of the stock are short sold. Based on an average daily volume of 2,260,000 shares, the days-to-cover ratio is currently 0.0 days. Based on an average daily volume of 2,260,000 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.6% of the shares of the stock are short sold.

Insider Transactions at Ainos

In related news, major shareholder Carbon Nano Technology Taiwan sold 7,000 shares of Ainos stock in a transaction on Monday, October 6th. The stock was sold at an average price of $3.59, for a total transaction of $25,130.00. Following the completion of the transaction, the insider directly owned 1,037,206 shares of the company’s stock, valued at approximately $3,723,569.54. The trade was a 0.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 9.79% of the company’s stock.

Ainos Stock Performance

Ainos stock opened at $3.30 on Friday. The company has a debt-to-equity ratio of 0.96, a quick ratio of 2.61 and a current ratio of 2.88. The stock has a fifty day moving average of $3.68 and a two-hundred day moving average of $3.15. The company has a market capitalization of $15.74 million, a price-to-earnings ratio of -0.66 and a beta of 2.25. Ainos has a fifty-two week low of $2.00 and a fifty-two week high of $5.00.

Ainos (NASDAQ:AIMD) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.99) earnings per share for the quarter.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on AIMD. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ainos in a report on Tuesday, October 14th. Wall Street Zen raised Ainos from a “sell” rating to a “hold” rating in a report on Friday, September 5th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Ainos Company Profile

Ainos, Inc, a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos’ cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a’s broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan.